Lyell Immunopharma, Inc. LYEL 深 滬
交易中 02-09 10:49:38 美东时间
21.52
-1.190
-5.24%
華盛通- 最 高23.375
- 今 開22.60
- 成交量 1.60万股
- 最 低 21.07
- 昨 收 22.71
- 總市值 4.57亿
- 52周最高 45.00
- 市盈率 靜 --
- 換手率 0.08%
- 52周最低 7.65
- 委 比 96.92%
- 總股本 2124.40万
- 歷史最高 396.80
- 量 比 0.99
- 振 幅 10.15%
- 歷史最低 7.80
- 每 手 1
- 風險率 7.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lyell Immunopharma pops on recent ASH data, immunotherapy expansion
Lyell Immunopharma (LYEL) is up ~17% on Monday as investors appear to digest positive data from one of its CAR-T blood cancer therapies presented earlier in December at the American Society of Hematol...
2025-12-23 03:56
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
Lyell Immunopharma announced strong clinical data for ronde-cel, a dual-targeting CD19/CD20 CAR T-cell therapy, in patients with relapsed/refractory large B-cell lymphoma (LBCL). In the third-line or later (3L+) setting, ronde-cel achieved a 93% overall response rate (ORR) and 76% complete response rate (CRR) with a median progression-free survival (PFS) of 18 months. In the second-line (2L) setting, the ORR was 83% and CRR 61%, with 70% of patie...
2025-12-07 21:30
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
HC Wainwright & Co. Maintains Neutral on Lyell Immunopharma, Raises Price Target to $20
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Lyell Immunopharma (NASDAQ:LYEL) with a Neutral and raises the price target from $10 to $20.
2025-11-24 20:53
Lyell Immunopharma reports Q3 results
Lyell Immunopharma press release (LYEL): Q3 GAAP EPS of -$2.13. Reported an adjusted net loss of $29.12M. Revenue of $0.01M (-55.9% Y/Y). More on Lyell Immunopharma Lyell Immunopharma buys exclusive g...
2025-11-14 01:35
斯丹赛生物结直肠癌CAR-T达成8.6亿元海外授权，临港南桥科技城助推园区生物医...
11月10日，上海临港所属的临港南桥科技城园区企业——斯丹赛生物技术有限公司宣布与美国Lyell Immunopharma公司达成一项重大授权合作，其核心产品...
2025-11-12 23:56
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
Lyell Immunopharma acquired LYL273, a GCC-targeted CAR T-cell therapy for metastatic colorectal cancer (mCRC), with promising Phase 1 results showing a 67% overall response rate and 83% disease control rate. LYL273 demonstrated manageable safety and enhanced CAR T-cell activity. The company plans to advance the therapy, aiming to address significant unmet needs in mCRC treatment. Lyell will host an investor webcast at 8:30 AM ET today.
2025-11-10 12:30
Lyell Immunopharma Appoints CEO Lynn Seely As Interim CFO And Veronica Sanchez Bulis As Principal Accounting Officer
On October 31, 2025, the Board of Directors of Lyell Immunopharma, Inc. (the "Company") appointed Lynn Seely, M.D., the Company's President, Chief Executive Officer and principal executive officer and a director of
2025-11-03 21:44
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
Lyell Immunopharma announced that two abstracts highlighting new clinical and translational data from the Phase 1/2 trial of rondecabtagene autoleucel (ronde-cel) for aggressive large B-cell lymphoma (LBCL) will be presented at the 67th ASH Annual Meeting. Ronde-cel, a next-generation dual-targeting CD19/CD20 CAR T-cell therapy, has shown promising complete response rates and safety profiles. The FDA has granted Regenerative Medicine Advanced The...
2025-11-03 14:00
